Bluebird bio — Investor Presentation (June 2023)
27 slides from Bluebird bio's investor presentation, Jun 12, 2023
Slide 1: bluebird bio Company Presentation June 2023
bluebird bio Company Presentation June 2023 NASDAQ: BLUE EXHIBIT 99.1
Slide 2: Forward-looking statements
CONFIDENTIAL These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other
Slide 3: To give patients and their families more bluebird days
CONFIDENTIAL 3 TO GIVE PATIENTS AND THEIR FAMILIES MORE BLUEBIRD DAYS
Slide 4: Demonstrating gene therapy expertise
CONFIDENTIAL ~22,000 patients potentially addressable with our 3 programs in the U.S.1 Demonstrating gene therapy expertise 1 Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512 521; Jul ’21 bbb analysis of Komodo patient-level claims data (Apr ’2
Slide 5: Three established gene therapy programs
CONFIDENTIAL Three established gene therapy programs • 63 patients treated across all clinical trials • 8 years of follow-up (n = 3) • In Phase 3 studies (n=41) – 90% of patients achieved transfusion independence • Safety profile generally consistent with that seen with cell collection and myeloabla
Slide 6: Momentum building with near-term commercial launches
CONFIDENTIAL Momentum building with near-term commercial launches; opportunity to deliver significant value for patients and shareholders 6 1,300-1,500 Patients potentially eligible for ZYNTEGLO® for beta-thalassemia ~20,000 40 Patients potentially eligible for SKYSONA® for Cerebral adrenoleukodystr
Slide 7: Inherited hemoglobin disorders
Inherited hemoglobin disorders
Slide 8: Launching now
CONFIDENTIAL Launching now 8
Slide 9: ZYNTEGLO commercial launch off to a strong start
CONFIDENTIAL ZYNTEGLO commercial launch off to a strong start 9 Access & ReimbursementPatient Interest QTC Network Launch built on three key pillars ZYNTEGLO ®
Slide 10: Qualified Treatment Center network being activated in waves
CONFIDENTIAL Fit-for-purpose Qualified Treatment Center (QTC) network being activated in waves 10 QTC: Qualified Treatment Center • Anticipated expansion to ~40-50 QTCs by YE 2023 to maximize opportunity for ZYNTEGLO and in anticipation of lovo-cel launch QTC growth aligned with demand Targeted QTC
Slide 11: Confident in timely, quality access and reimbursement at $2.8M price
CONFIDENTIAL Confident in timely, quality access and reimbursement with upfront payment at $2.8M price 11 S IMP LE A N D IN N OVATIVE PAY MEN T STRATEGY EN COU RAG IN G PAY ER IN TERAC TIONS 1 Date on file 2 Weiss et al. 2019 3 TIF Guidelines P RI CE T I ED TO RECOG N IZ ED VA LU E Beta-thalassemia
Slide 12: Early indications show value of ZYNTEGLO is recognized
CONFIDENTIAL Early indications show value of ZYNTEGLO is recognized 12 S IMP LE A N D IN N OVATIVE PAY MEN T STRATEGY EN COU RAG IN G PAY ER IN TERAC TIONS P RI CE T I ED TO RECOG N IZ ED VA LU E Beta-thalassemia requiring regular RBC transfusions is associated with: • $6.4 million average lifetime
Slide 13: ZYNTEGLO manufacturing allows flexible scheduling
CONFIDENTIAL ZYNTEGLO® manufacturing allows for flexible scheduling and is designed to deliver high quality drug product 13 Apheresis and Cell Collection Drug Product Manufacturing and Testing Drug Product Ready to Ship Infusion and Recovery 70-90 Days Occurs at QTC Occurs at CMO Bulk of time spent
Slide 14: Seamless transition to commercializing lovo-cel
CONFIDENTIAL ZYNTEGLO expected to enable seamless transition to commercializing lovo-cel for sickle cell disease 14 ZYNTEGLO ® Access & ReimbursementPatient Interest QTC Network Established confidence with payers Same treating physicians Same QTC network LOVO-CEL
Slide 15: Large patient population, significant unmet need in sickle cell disease
CONFIDENTIAL L A R G E PAT I E N T P O P U L AT I O N S I G N I F I C A N T U N M E T N E E D M E A N I N G F U L O P P O R T U N I T Y 1 CDC 2 Data on file3 Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 3 Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Di
Slide 16: lovo-cel BLA submitted in April 2023
CONFIDENTIAL lovo-cel BLA submitted in April 2023 BLA includes: HGB-206 Group C as primary basis of effectiveness 36 patients with a median 32 months of follow- up and 2 patients in the HGB-210 study with 18 months of follow-up Pivotal study HGB-206; largest gene therapy study in SCD to date with
Slide 17: Planned 2023 network expansion for lovo-cel
CONFIDENTIAL Planned 2023 network expansion ensures QTCs are in place and ready to treat appropriate SCD patients upon FDA approval of lovo-cel 17 *Graphic is illustrative and subject to change as final QTC network is determined; Activated QTC defined as Qualified Treatment Center with a signed MSA;
Slide 18: SKYSONA
SKYSONA®
Slide 19: SKYSONA launching now
CONFIDENTIALJune 9, 2023 Launching now • First commercial infusion has been completed; in total cell collection completed for three patients for SKYSONA • Three activated QTCs • Zero ultimate denials to date; payers recognize value and urgency to treat • Anticipate 5-10 patient starts in 2023 19 Ear
Slide 20: Closing
Closing
Slide 21: Strong financial position – cash burn and runway horizon
CONFIDENTIAL Strong financial position – cash burn and runway horizon 21 C A SH & C A SH E Q U IV A LE N TS Current cash runway into Q4 20242 Continuing to strengthen balance sheet beyond Q4 2024 1. Cash balance contains $45m in restricted cash.; 2. Without the release of our restricted cash, we est
Slide 22: Upcoming milestones
CONFIDENTIAL First to market gene therapy for inherited hemoglobin disorders in the U.S. Proving our commercial model Significant value driver o Anticipate BLA acceptance in Q2 2023 o Commercial launch expected early 2024 o First commercial revenue expected in Q2 2023 o Continued launch expansion th
Slide 23: Setting the standard and proving the gene therapy commercial model
CONFIDENTIAL bluebird bio: Setting the standard and proving the gene therapy commercial model 23 Demonstrating gene therapy expertise across clinical, regulatory and commercial Momentum building with near-term commercial launches Opportunity to deliver significant value for patients and shareholders
Slide 24: Thank you
Slide 25: ZYNTEGLO approval underscored by clinical study data
CONFIDENTIAL ZYNTEGLO® approval is underscored by impressive clinical study data 25 **After a planned orthopedic surgery, the patient had blood loss, which required 1 packed red blood cell transfusion Data as of July 2022 • 90% of patients achieved transfusion independence (TI) and normal or near-no
Slide 26: lovo-cel: most advanced sickle cell disease gene therapy program
CONFIDENTIAL lovo-cel: most advanced sickle cell disease gene therapy development program in the industry Update on Pivotal Cohort (HGB 206 Group C) Presented at ASH 2022 • 96%experienced complete resolution of severe VOEs through 24 months of follow-up (ASH 2022) • As of August 2022, 50 patients ha
Slide 27: SKYSONA FDA approval based on post hoc enrichment analysis
CONFIDENTIAL FDA approval was based on a post hoc enrichment analysis of 24- month improvement in major functional disability (MFD) free survival SKYSONA treated patients (n = 11) had an estimated 72% likelihood of MFD-free survival at 24 months compared to untreated patients in a natural history st